Loading resource…

CARDIO-TTRansform Investigators
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a life-threatening condition characterized by the accumulation of misfolded transthyretin proteins in the heart. The study evaluates the efficacy of eplontersen, which aims to reduce the production of hepatic TTR. This phase 3 trial involved a double-blind methodology, comparing eplontersen to a placebo over a period of 140 weeks, focusing on cardiovascular outcomes.
No account needed